



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Paper

Pharmaceutical Formulations Using 3D Printing: Advances and Challenges

Satyam Sharma, Dr. Sudha Rathod, Anjali Rai*

Oriental College of Pharmacy, Sanpada Navi Mumbai.

ARTICLE INFO

Published: 25 Sept 2026

Keywords:

3D printing, pharmaceutical formulations, personalized medicine, drug delivery, additive manufacturing, regulatory challenges

DOI:

10.5281/zenodo.22955735

ABSTRACT

Over the past decade, the integration of three-dimensional (3D) printing into pharmaceutical sciences has emerged as a transformative approach for drug development and personalized medicine. Initially developed for rapid industrial prototyping, 3D printing has evolved into a versatile tool capable of fabricating customized, complex, and multi-functional drug delivery systems. The FDA's 2015 approval of Spritam (levetiracetam), the world's first 3D-printed oral drug, marked a pivotal moment, validating the clinical potential of additive manufacturing in the pharmaceutical sector. 3D printing enables the layer-by-layer construction of dosage forms with intricate geometries and tailored drug release kinetics. Techniques such as fused deposition modelling (FDM), inkjet printing, stereolithography (SLA), and semi-solid extrusion (SSE) have been adapted for pharmaceutical use, offering unique benefits regarding material compatibility, resolution, and scalability. These innovations have enabled the development of orodispersible tablets, polypills, pediatric and geriatric formulations, and implantable drug systems. Recent advances emphasize drug-excipient compatibility, print resolution, reproducibility, and overcoming thermal stability and post-processing challenges. The incorporation of AI-based formulation modeling, 4D printing (dynamic structures), and bioprinting of tissues and scaffolds marks the frontier of pharmaceutical innovation. Challenges include scaling production, ensuring GMP compliance, and validating digital workflows. Regulatory bodies such as the FDA and EMA are actively working on integrating these technologies within regulatory frameworks. In conclusion, the past ten years have highlighted 3D printing's potential to revolutionize pharmaceutical manufacturing, particularly in personalized medicine. As technological, regulatory, and material science barriers are addressed, 3D printing is poised to become integral to the pharmaceutical industry's future.

*Corresponding Author: Anjali Rai

Address: Oriental College of Pharmacy, Sanpada Navi Mumbai.

Email ✉: anjali.rai@ocp.edu.in

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



INTRODUCTION

Pharmaceutical printing encompasses printing technologies used in drug product manufacturing and packaging. This includes marking tablets, capsules, and labels, and plays vital roles in product identification, patient compliance, traceability, and anti-counterfeiting.

Early uses of pharmaceutical printing include imprinting identification codes or dosage details on dosage forms, reducing medication errors. Inkjet, laser, and pad printing have evolved into high-resolution digital printing capable of handling small, complex surfaces.

In packaging, essential information—such as drug name, dosage, batch number, and expiry date—is printed, often with barcodes or QR codes, enhancing inventory tracking and safety. Regulatory authorities enforce stringent guidelines for compliance and public safety.

The most transformative development in pharmaceutical printing has been the use of **3D printing** to manufacture drug dosage forms with precise control over shape, dosage, and release profile. With the FDA approval of Spritam in 2015, 3D printing became a new frontier in personalized medicine.

3D printing builds objects from digital models, offering unmatched flexibility. Unlike traditional manufacturing, it supports rapid prototyping and personalized therapies with complex drug release behaviors—marking a new era in pharmaceutical care.

A Brief History of 3D Printing

Early Developments (1980s)

The concept emerged in 1981 with Dr. Hideo Kodama's proposal of UV-cured photopolymer printing. The breakthrough came in 1984 when Charles Hull invented stereolithography (SLA), founding 3D Systems and introducing the STL file format, still in use today.

1990s: Expansion

This decade saw the rise of techniques like:

- **SLS** (Selective Laser Sintering): Lasers fuse powder materials.
- **FDM** (Fused Deposition Modeling): Thermoplastic extrusion for layering.
- **LOM** (Laminated Object Manufacturing): Layered paper/plastic fused and cut.

3D printing remained costly, largely confined to industrial prototyping.

2000s: Accessibility

Open-source initiatives like the RepRap project and patent expirations (e.g., FDM in 2009) led to reduced costs and widespread adoption, including in small businesses and education.

2010s: Industry Adoption

Applications expanded across:

- **Healthcare**: Custom prosthetics, implants, bioprinting.
- **Aerospace & Automotive**: Lightweight parts.
- **Construction**: 3D-printed homes.
- **Consumer goods**: Personalized products.

3D printing gained political attention and became integral to innovation.

2020s: Strategic Use

Key developments include:

- **COVID-19 response**: PPE, ventilator parts.
- **Advanced materials**: Graphene, ceramics, biodegradable plastics.
- **Integration with AI and IoT**: Enhanced precision and monitoring.
- **Sustainability**: Localized, waste-reducing production.

Now, 3D printing is a foundational element of **Industry 4.0**.



Innovations in 3D Printing for Pharmaceutical Formulations

Personalized Medicine

Techniques like FDM and inkjet printing enable dose tailoring for individual patients. Polypills can combine multiple APIs with distinct release profiles (e.g., captopril and nifedipine).

Complex Drug Delivery

Technologies like SLS and SSE allow construction of porous structures and hydrogels for immediate, sustained, or pulsatile release.

Novel Dosage Forms

Beyond tablets, 3D printing supports films, patches, and implants. Inkjet methods can print proteins (e.g., lysozyme) for mucosal delivery.

Regulatory & Commercial Progress

FDA-approved products like Triastek's T19 and companies like FabRx show commercial viability. AI integration is also improving formulation modeling.

Sustainability

Using biodegradable materials (e.g., PVA) and on-demand production reduces environmental footprint.

Challenges in 3D Printing for Pharmaceuticals

Regulatory & Legal

- Lack of standardized frameworks.
- In-process quality assurance is complex.
- Decentralized production increases risks of counterfeiting and data breaches.

Material Limitations

- Limited number of printable, approved excipients.
- High temperatures and UV exposure may degrade APIs.

Technical & Economic Barriers

- Printer design not tailored for pharma.
- Low throughput and high cost of industrial systems.
- Post-processing like drying or curing adds complexity.

Software & Security

- No specialized pharmaceutical CAD tools.
- Risk of IP theft or tampering with digital drug models.

Patient Acceptance

- Public trust and clinical training are needed for adoption.
- Safety concerns over “printed pills” must be addressed.

Medical Benefits of 3D Printing

1. **Personalized Dosages:** Adjusted for weight, age, or genetics.
2. **Improved Compliance:** Flavored, fast-dissolving tablets for pediatric or geriatric patients.
3. **Controlled Release:** Multi-layered tablets for tailored kinetics.
4. **Polypills:** Reduced pill burden in chronic diseases.
5. **On-Demand Manufacturing:** Quick production in hospitals or remote locations.
6. **Targeted Delivery:** Drug release at specific GI tract locations.
7. **Rapid Prototyping:** Accelerated R&D and formulation testing.
8. **Improved Stability:** Protective matrices enhance shelf life.

Clinical Examples:

- **Spritam:** Fast-melt epilepsy drug using binder jetting.
- **Pediatric Ibuprofen:** Chewable FDM-printed tablets.



- **Polypills:** Cardiovascular meds combined into one dose.

Types of 3D Printing in Pharmaceuticals

Technique	Principle	Materials	Applications
FDM	Extrusion of heated filaments	PVA, PLA, HPC	Polypills, chewables
Inkjet	Droplet deposition	API solutions	Oral films, precision dosing
Binder Jetting	Binder fuses powder	Lactose, ethanol binders	Fast-melt tablets
SLA	UV-curing resin layers	Photopolymers	Scaffolds, implants
SLS	Laser sinters powders	Polymer blends	Controlled-release tablets
SSE	Semi-solid extrusion	Hydrogels, waxes	Patches, thermolabile drugs

From Lab Scale to Industry

Lab-Scale Applications

- Prototype development
- Compatibility testing
- Small-batch custom drugs

Industrial Scale Challenges

- Process standardization and speed
- GMP-compliant bulk material handling
- Regulatory documentation and QA

Supporting Advancements

- GMP-ready printers
- AI-enabled automation
- Modular hospital-based units
- Digital infrastructure (e.g., EBRs, PAT)

Industrial Use Cases:

- **Aprecia Pharma:** Spritam via binder jetting.
- **FabRx:** Custom pediatric printlets.
- **Triastek:** Delayed release via extrusion.
- **Multiply Labs:** Robotic capsule lines.

SUMMARY

3D printing is revolutionizing pharmaceutical formulation by enabling personalized, on-demand, and complex drug therapies. While numerous advances have been made—from regulatory approval to commercial production—significant barriers remain, including material limitations, regulatory gaps, and scalability.

However, collaborative innovation across pharma, engineering, and regulatory domains promises a

transformative future. With continued research and integration into digital health frameworks, 3D printing is set to become a cornerstone of modern, personalized medicine.

REFERENCES

1. U.S. Approves First 3D Printed Pill. Time. 2015.
2. 3D Printing of Customized Drug Delivery Systems with Controlled Architecture via Reversible Addition-Fragmentation Chain Transfer Polymerization. Advanced Engineering Materials. 2023.
3. Evolution, integration, and challenges of 3D printing in pharmaceutical applications: A comprehensive review. Bioprinting. 2024.
4. 3D Printing as a Promising Tool in Personalized Medicine. AAPS Pharm SciTech. 2020.
5. 3D Printing Technologies in Personalized Medicine, Nanomedicines, and Biopharmaceuticals. PMC. 2023.
6. 3D Printing of Drug Delivery Systems Enhanced with Micro/Nano-Technology. Advanced Drug Delivery Reviews. 2025.
7. Empowering Precision Medicine: The Impact of 3D Printing on Personalized Therapeutic. AAPS Pharm SciTech. 2023.



8. D Printing in Drug Delivery and Biomedical Applications: A State-of-the-Art Review. MDPI. 2021.
9. Approaches of 3D Printing in Current Drug Delivery. Sensors International. 2022.
10. Emerging 3D Printing Technologies for Drug Delivery Devices: Current Status and Future Perspective. Advanced Drug Delivery Reviews. 2021.
11. 3D Printing in Medicine: Technology Overview and Drug Delivery Applications. Annals of 3D Printed Medicine. 2021.
12. Revolutionizing Pharmaceutical Manufacturing: Advances and Challenges of 3D Printing System and Control. arXiv. 2024.
13. 13.A Comparative Review of 3D Printing Technologies and Their Applications: A Systematic Review for Future of Medicine Fabrication. International Journal of Pharmaceutical Investigation. 2021.
14. 3D Printing of Pharmaceutical Application: Drug Screening and Drug Delivery. MDPI. 2021.
15. First 3D-Printed Pill Gets Green Light in US. Wired. 2015.
16. The ‘Chemputer’ That Could Print Out Any Drug. The Guardian. 2012.
17. A Lab Just 3D-Printed a Neural Network of Living Brain Cells. Wired. 2023.
18. Wang, S., Lin, L., Zhang, Y., & Shi, Y. (2023). A review of 3D printing technology in pharmaceuticals: Technology and applications, now and future. *Pharmaceutics*, 15(2), 416. <https://doi.org/10.3390/pharmaceutics15020416>
19. Kumar, R., Sharma, S., & Tiwari, R. (2024). Revolutionizing pharmaceutical manufacturing: Advances and challenges of 3D printing systems. *arXiv preprint arXiv:2402.05431*.
20. Parhi, R. (2024). Evolution, integration, and challenges of 3D printing in pharmaceutical applications: A comprehensive review. *Asian Journal of Pharmaceutical Sciences*. <https://doi.org/10.1016/j.ajps.2024.01.002>
21. Chan, H. K., Heng, P. W. S., & Sia Heng, P. W. (2021). A review of three-dimensional printing for pharmaceutical applications: Quality control, risk assessment and future perspectives. *International Journal of Pharmaceutics*, 599, 120443. <https://doi.org/10.1016/j.ijpharm.2021.120443>
22. Goyanes, A., Fina, F., & Basit, A. W. (2018). 3D printing in pharmaceutical and medical applications – recent achievements and challenges. *Pharmaceutical Research*, 35(2), 34. <https://doi.org/10.1007/s11095-017-2368-0>
23. Zema, L., Melocchi, A., Maroni, A., & Gazzaniga, A. (2017). Three-dimensional printing of medicinal products and the challenge of personalized therapy. *Journal of Pharmaceutical Sciences*, 106(7), 1697–1705. <https://doi.org/10.1016/j.xphs.2017.03.021>
24. Rahman, Z., Barakh Ali, S. F., & Khan, M. A. (2016). Three-dimensional printing for pharmaceutical applications: Quality control, risk assessment and future perspectives. *International Journal of Pharmaceutics*, 499(1-2), 443–450.
25. Trenfield, S. J., Awad, A., Goyanes, A., Gaisford, S., & Basit, A. W. (2019). Shaping the future: recent advances of 3D printing in drug delivery and healthcare. *Expert Opinion on Drug Delivery*, 16(10), 1081–1094.
26. Mohapatra, S., Kumar, A., & Rautray, T. R. (2021). Semisolid extrusion 3D printing in drug delivery and biomedicine. *Journal of Controlled Release*, 338, 536–553.
27. Sadia, M., Arafat, B., Ahmed, W., Forbes, R. T., & Alhnan, M. A. (2017). 3D inkjet printing of tablets exploiting bespoke complex



- geometries for controlled and tuneable drug release. *Journal of Controlled Release*, 261, 207–215.
28. Cader, H. K., et al. (2020). 3D printing of paediatric dosage forms with precise layer-wise dose adjustments via pressure-assisted microsyringe printing. *European Journal of Pharmaceutics and Biopharmaceutics*, 151, 18–27.
29. Eleftheriadis, G. K., et al. (2019). Water-based 3D inkjet printing of an oral pharmaceutical dosage form. *International Journal of Pharmaceutics*, 564, 428–435.
30. Katstra, W. E., et al. (2015). Oral dosage forms fabricated by three-dimensional printing™. *European Journal of Pharmaceutics and Biopharmaceutics*, 58(2), 317–326.
31. Goyanes, A., et al. (2015). Fabrication of extended-release patient-tailored prednisolone tablets via fused deposition modelling (FDM) 3D printing. *European Journal of Pharmaceutical Sciences*, 68, 11–17.
32. Conceição, J., et al. (2018). 3D extrusion printing of high drug loading immediate release paracetamol tablets. *International Journal of Pharmaceutics*, 547(1–2), 269–278.
33. Skowrya, J., Pietrzak, K., Alhnan, M. A. (2019). Hydroxypropyl- β -cyclodextrin-based fast dissolving carbamazepine printlets prepared by semisolid extrusion 3D printing. *Carbohydrate Polymers*, 221, 25–32.
34. Saviano, M., et al. (2018). Channelled tablets: an innovative approach to accelerating drug release from 3D printed tablets. *Journal of Controlled Release*, 271, 148–155.
35. éstraete, G., et al. (2019). Poly(vinyl alcohol) 3D printed tablets: effect of polymer particle size on drug loading. *International Journal of Pharmaceutics*, 556, 214–222.
36. Khaled, S. A., Burley, J. C., Alexander, M. R., Yang, J., & Roberts, C. J. (2018). 3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles. *Journal of Controlled Release*, 217, 308–314.
37. Scoutaris, N., Ross, S. A., & Douroumis, D. (2018). 3D-printed “starmix” drug loaded dosage forms for paediatric applications. *Pharmaceutical Research*, 35(3), 34.
38. Pitzanti, G., et al. (2022). 3D printing: an appealing technology for the manufacturing of solid oral dosage forms. *Journal of Pharmacy and Pharmacology*, 74(6), 741–752.
39. Parhi, R., & Jena, G. K. (2022). An updated review on application of 3D printing in fabricating pharmaceutical dosage forms. *Drug Delivery and Translational Research*, 12(5), 1090–1103.
40. Gaurav, S., et al. (2021). Recent update of 3D printing technology in pharmaceutical formulation development. *Journal of Biomaterials Science, Polymer Edition*, 32(5), 715–734.
41. Racaniello, G. F., et al. (2024). Innovative pharmaceutical techniques for pediatric dosage forms. *Journal of Pharmaceutical Sciences*, 113(1), 23–32.
42. Tian, P., et al. (2019). Applications of excipients in the field of 3D printed pharmaceuticals. *Drug Development and Industrial Pharmacy*, 45(1), 1–12.
43. Ligon, S. C., et al. (2017). Polymers for 3D printing and customized additive manufacturing. *Chemical Reviews*, 117(15), 10212–10290.
44. Verstraete, G., et al. (2019). Poly (vinyl alcohol) 3D printed tablets: Effect of polymer particle size on drug loading. *International Journal of Pharmaceutics*, 556, 214–222.



45. Cholakova, D., et al. (2022). Self-emulsification in chemical and pharmaceutical technologies. *arXiv preprint arXiv:2201.03212*.
46. Uddin, M. J., et al. (2021). Opportunities and challenges of three-dimensional printing technology in pharmaceutical formulation development. *Pharmaceuticals*, 14(2), 147.
47. Bhusnure, O. G., et al. (2024). 3D printing processes in precise drug delivery for personalized medicine. *Journal of Drug Delivery Science and Technology*, 86, 104541.

HOW TO CITE: Satyam Sharma, Dr. Sudha Rathod, Anjali Rai, Pharmaceutical Formulations Using 3D Printing: Advances and Challenges, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 9, 3259-3265, <https://doi.org/10.5281/zenodo.22955735>

